Discover the people, geography, and economy.
Highest educational attainment in the OECD.
Among the lowest costs in the G7.
Generous incentives for R&D.
Part of the $20-trillion NAFTA market.
Top ranked on global indices.
Get information on what Ontario can offer your business.
Watch videos that show how companies across industries thrive here.
Canada's largest chemical manufacturing sector
Ontario has the right environment for robotics companies to flourish
Canada’s top tourism market: 55% of all international visitors.
PlantForm Corporation has patented a plant-based manufacturing system for a wide range of pharmaceuticals, including antibodies, therapeutic proteins, and vaccines to treat cancer, HIV/AIDS, Ebola virus, arthritis, Crohn's and more. The manufacturing system is based on biopharming, a complex technology that requires workers with a superior scientific skillset. Fortunately, Ontario has such talent in abundance.
Biopharming refers to the use of genetically engineered plants to produce a wide range of pharmaceuticals and industrial products that are commonly known as "biologics," since they are derived from living organisms. PlantForm's molecular farming platform is licensed from the University of Guelph, where it was originally developed, and the company has labs in Guelph, plus offices in Toronto, Sarnia and Rio de Janeiro, Brazil.
PlantForm's vivoXPRESS® biopharming system uses a particular strain of leafy tobacco plant, permeated with bacteria that contain the genes needed to produce the desired drug. Unlike the type grown for smoking, these tobacco plants are far smaller and grow well indoors. They are ideal for the job, says PlantForm president and CEO Don Stewart, because they provide "a large amount of leaf on a small footprint" so the company can maximize production.
Because production costs are approximately one-tenth those of mammalian-cell fermentation systems, PlantForm's technology is uniquely positioned to capitalize on the growing global demand for affordable biologics. "Essentially, we're using plants as bioreactors, so it's comparatively cheap," says Stewart.
In addition to lower costs, PlantForm's process offers substantial benefits over mammalian- and bacterial-cell fermentation systems:
The province has come through with access to talent, says Stewart. When PlantForm established its research facility in Guelph, it had no trouble attracting qualified staff from the surrounding areas. "There's a strong talent and technology base here and the province is helping us exploit that."
Stewart has also been impressed by the MaRS Discovery District, and appreciates the unparalleled access to knowledge, expertise, mentoring and training. "Ontario has a long-term supportive view of advanced manufacturing, so we're a good mesh for its objectives. The province is doing everything it can to help us."
PlantForm has raised about $16 million in equity, contracts and grants. Stewart says securing its first significant investor, UK-based Atlantic Asset Trust, was a major milestone. Now the company is seeking $35 million in additional financing to bring its first drug candidate, biosimilar trastuzumab (Herceptin®)—a breast cancer treatment—into clinical trials.
The company plans to start selling Herceptin® in Europe in 2020, followed closely by Canada and then the United States. It expects to be making $100 million in sales by 2020-2021.
Next in the pipeline will be an antidote to ricin, part of the company's program on bioterrorism countermeasures. Defense Research and Development Canada developed the drug and has teamed up with PlantForm to manufacture and commercialize it. Stewart says he has no doubt it will be the best-in-class drug (for that purpose) in the world.
PlantForm's third major program is the development of biosimilar adalimumab (Humira®), used in arthritis and Crohn's disease. It is being developed as a joint venture with Axis Biotec Brasil.
Stewart says his company is scouting the Mississauga area, west of Toronto, to build a $15- to $20-million facility. Part of the reason he likes the area is that it's home to many major pharmaceutical firms, and he'll have ready access to talent.
Stewart says it's exciting to lead a firm that is commercializing an Ontario-based technology and bringing it to world markets. "The technology we've licensed and further developed has attracted international interest, from Brazil to China," says Stewart. "We're using Ontario's knowledge base and expertise to create a company that will address world needs."
August 9, 2016
Made-in-Ontario: Hamilton Health Sciences Pilots Life-Saving App
Bringing precision to orthopaedic surgery
Canada named top 3 destination for international job seekers
Nuvation: in the driver's seat of autonomous car development
Advancing innovation in Ontario with IBM Watson
Bayer and Versant bet big on centre for regenerative medicine
Shifting the way physicians engage patients
WinMagic: Meeting the challenge of cybersecurity threats in the modern enterprise
Spartan Bioscience: Creating the world's smallest molecular diagnostics device
Intercept Pharmaceuticals brings innovative firm back home to Ontario
Global specialty biopharma leader joins the biotech ecosystem of Ontario, Canada
Canadian cities dominate the 2017 Intelligent Community Forum's 'Smart21'
Receive the latest news and updates from Invest in Ontario.
Sign up now
All figures are in Canadian dollars unless otherwise noted. Information is accurate at the time of publication.